Ajulemic acid (CT-3, IP-751, 1′,1′-dimethylheptyl-Δ8- tetrahydrocannabinol-11-oic acid) (AJA) has a cannabinoid-derived structure; however, there is no evidence that it produces psychotropic actions when given at therapeutic doses. In a variety of animal assays, AJA shows efficacy in models for pain and inflammation. Furthermore, in the rat adjuvant arthritis model, it displayed a remarkable action in preventing the destruction of inflamed joints. A phase-2 human trial with, chronic, neuropathic pain patients suggested that AJA could become a useful drug for treating this condition. Its low toxicity, particularly its lack of ulcerogenicity, further suggests that it will have a highly favorable therapeutic index and may replace some of the current anti-inflammatory/analgesic medications. Studies to date indicate a unique mechanism of action for AJA that may explain its lack of adverse side effects. Copyright ©2003. All Rights Reserved.
CITATION STYLE
Burstein, S. (2005). Ajulemic acid (IP-751): Synthesis, proof of principle, toxicity studies, and clinical trials. AAPS Journal, 7(1). https://doi.org/10.1208/aapsj070115
Mendeley helps you to discover research relevant for your work.